Single nucleotide polymorphisms might influence chemotherapy induced nausea in women with breast cancer

Oliva, Delmy; Nilsson, Mats; Andersson, Bengt-Åke; Sharp, Lena; Lewin, Freddi; Laytragoon‐Lewin, Nongnit

doi:10.1016/j.ctro.2016.12.001

Cited by 11 publications

(13 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This indicates the impact CINV had on the daily life of these women. The study showed that most women estimated CINV with great variety and some of the women did not follow the pattern from other studies [58,118].…”

Section: Discussioncontrasting

confidence: 58%

“…Antiemetic management is stated by a guideline from the Southeastern health region in Sweden based on the American Society of Clinical Oncology antiemetic guideline [57]. Despite all new drugs, nausea remains a clinical problem [58,59] (Table 1).…”

Section: Mechanism Of Nauseamentioning

confidence: 99%

“…SNP-analysis can be done before treatment and with certainty identify patients with an increased risk for developing the studied side effects and thus could be helpful to personalize treatments, information and self-care advice [58,95].…”

Section: Genetics Single Nucleotide Polymorphism Definition and Application On The Clinical Workmentioning

confidence: 99%

See 2 more Smart Citations

Prediction of side effects from anticancer treatment with the purpose of increasing quality of life

Oliva

2019

Linköping University Medical Dissertations

Self Cite

View full text Add to dashboard Cite

AbbreviationsABCA1 ATP-binding cassette transporter A member1 ANV Anticipatory Nausea and Vomiting ARSR Acute Radiation Skin Reactions ATM Ataxia telangiectasia mutated BC Breast cancer BRCA1 Breast cancer 1 BRCA2 Breast cancer 2 Casp 8 Caspase 8, apoptosis-related cysteine peptidase Casp 9 Caspase 9, apoptosis-related cysteine peptidase CCL2 Chemokine (C-C motif) ligand 2 CCL4 Chemokine (C-C motif) ligand 4 CCL5/RANTES Chemokine (C-C motif) ligand 5 CCND3 Cyclin D3 CDKN2A Cyclin-dependent kinase inhibitor 2A CI Confidence interval CINV Chemotherapy Induced Nausea and Vomiting CRP C-reactive protein CRF Case Report Form

show abstract

Section: Discussioncontrasting

confidence: 58%

Section: Mechanism Of Nauseamentioning

confidence: 99%

See 1 more Smart Citation

Prediction of side effects from anticancer treatment with the purpose of increasing quality of life

Oliva

2019

Linköping University Medical Dissertations

Self Cite

View full text Add to dashboard Cite

show abstract

“…When comparing colorectal neoplasia, a statistically significant difference was observed for the symptom of nausea when compared to breast neoplasia. Different results were found in the study of Oliva, et al (21) in Sweden between chemotherapy treatment in women with breast cancer and who exhibited prevalent symptom of nausea (21) .…”

Section: Discussionmentioning

confidence: 79%

Gastrointestinal Changes During Nutritional Follow-Up of Cancer Patients Undergoing Outpatient Chemotherapy

Saragiotto

Leandro-Merhi

Aquino

et al. 2020

Arq. Gastroenterol.

View full text Add to dashboard Cite

BACKGROUND: Cancer patients may have gastrointestinal changes that influence nutritional status. OBJECTIVE: To investigate the occurrence of gastrointestinal changes resulting from outpatient chemotherapy treatment in cancer patients. METHODS: In a retrospective longitudinal study, the nutritional status and chemotherapy gastrointestinal changes (nausea, vomit, diarrhea, constipation, mucositis, dysphagia, xerostomia, inappetence, dysgeusia and heartburn) in cancer patients (n=187) were investigated in an outpatient follow-up. For the study of the parameters over time, the generalized estimating equation (GEE) method was used. Kruskal-Wallis, Mann-Whitney tests and Spearman coefficient, at a significance level of 5% were also used. RESULTS: The majority of the patients were female (63.64%) and the mean age was 57.5±12.1 years. The most frequent symptoms were nausea (18.54%); inappetence (18.31%); intestinal constipation (11.58%); diarrhea (7.98%); xerostomia (7.59%) and vomiting (7.43%). The nutritional status did not exhibit any relevant changes (P=0.7594). However, a higher prevalence of eutrophy was observed, followed by overweight; vomiting exhibited a significant difference (P=0.0211). The nausea symptom exhibited a significant difference with a higher prevalence of colorectal neoplasia when compared to breast neoplasia (P=0.0062); as well as vomiting in lung and colorectal neoplasias (P=0.0022), and dysphagia, in head and neck neoplasia, when compared to other neoplasms (P<0.001). There was a statistically significant difference between the number of medical appointments and gender (P=0.0102) and between dysphagia and gender (P<0.0001). CONCLUSION: The study findings enhance the need for signs and symptoms follow up, as well as nutritional status follow up of patients undergoing outpatient chemotherapy.

show abstract

“…The complete pathophysiology of CINV is not known but gastrointestinal (GI) side effects associated with anticancer chemotherapy are traditionally thought to be attributable to mucosal damage [ 23 ]. Nausea is complex in nature and probably depending on more than one etiological factor [ 24 ]. Different pathways have been identified for acute and delayed CINV [ 25 ].…”

Section: Introductionmentioning

confidence: 99%

Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients

et al. 2018

View full text Add to dashboard Cite

The differences in patients’ response to the same medication, toxicity included, are one of the major problems in breast cancer treatment. Chemotherapy toxicity makes a significant clinical problem due to decreased quality of life, prolongation of treatment and reinforcement of negative emotions associated with therapy.In this study we evaluated the genetic and clinical risk factors of FAC chemotherapy-related toxicities in the group of 324 breast cancer patients. Selected genes and their polymorphisms were involved in FAC drugs transport (ABCB1, ABCC2, ABCG2,SLC22A16), metabolism (ALDH3A1, CBR1, CYP1B1, CYP2C19, DPYD, GSTM1, GSTP1, GSTT1, MTHFR,TYMS), DNA damage recognition, repair and cell cycle control (ATM, ERCC1, ERCC2, TP53, XRCC1).The multifactorial risk models that combine genetic risk modifiers and clinical characteristics were constructed for 12 toxic symptoms. The majority of toxicities was dependent on the modifications in components of more than one pathway of FAC drugs, while the impact level of clinical factors was comparable to the genetic ones. For the carriers of multiple high risk factors the chance of developing given symptom was significantly elevated which proved the factor-dosage effect. We found the strongest associations between concurrent presence of clinical factors - overall and recurrent anemia, nephrotoxicity and early nausea and genetic polymorphisms in genes responsible for DNA repair, drugs metabolism and transport pathways. These results indicate the possibility of selection of the patients with expected high tolerance to FAC treatment and consequently with high chance of chemotherapy completion without the dose reduction, treatment delays and decline in the quality of life.

show abstract

Single nucleotide polymorphisms might influence chemotherapy induced nausea in women with breast cancer

Cited by 11 publications

References 35 publications

Prediction of side effects from anticancer treatment with the purpose of increasing quality of life

Prediction of side effects from anticancer treatment with the purpose of increasing quality of life

Gastrointestinal Changes During Nutritional Follow-Up of Cancer Patients Undergoing Outpatient Chemotherapy

Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients

Contact Info

Product

Resources

About